Natera, Inc. $NTRA Shares Purchased by JPMorgan Chase & Co.

JPMorgan Chase & Co. boosted its stake in Natera, Inc. (NASDAQ:NTRA) by 10.5% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 12,854,334 shares of the medical research company’s stock after purchasing an additional 1,225,420 shares during the period. JPMorgan Chase & Co. owned about 9.29% of Natera worth $2,944,800,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Palladiem LLC acquired a new stake in Natera in the 4th quarter valued at approximately $31,000. Horizon Investments LLC acquired a new stake in Natera in the 3rd quarter valued at approximately $32,000. Flagship Harbor Advisors LLC acquired a new stake in Natera in the 4th quarter valued at approximately $41,000. Sound Income Strategies LLC increased its holdings in Natera by 20.0% in the 4th quarter. Sound Income Strategies LLC now owns 270 shares of the medical research company’s stock valued at $62,000 after purchasing an additional 45 shares during the last quarter. Finally, TD Waterhouse Canada Inc. acquired a new stake in Natera in the 4th quarter valued at approximately $62,000. Institutional investors and hedge funds own 99.90% of the company’s stock.

Analyst Upgrades and Downgrades

NTRA has been the subject of several research reports. Evercore reiterated an “outperform” rating and issued a $270.00 target price on shares of Natera in a report on Friday, May 8th. Wolfe Research began coverage on shares of Natera in a report on Tuesday, June 2nd. They issued an “outperform” rating and a $260.00 target price for the company. Wells Fargo & Company raised their price target on shares of Natera from $215.00 to $220.00 and gave the company an “equal weight” rating in a research report on Friday, May 8th. Robert W. Baird set a $265.00 price target on shares of Natera in a research report on Friday, May 8th. Finally, Wall Street Zen cut shares of Natera from a “buy” rating to a “hold” rating in a research report on Saturday, May 9th. Two research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $256.12.

Insider Buying and Selling

In other news, CEO Steven Leonard Chapman sold 41,124 shares of Natera stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $221.03, for a total transaction of $9,089,637.72. Following the completion of the sale, the chief executive officer directly owned 108,743 shares of the company’s stock, valued at approximately $24,035,465.29. The trade was a 27.44% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Roelof Botha sold 78,000 shares of Natera stock in a transaction on Monday, June 1st. The stock was sold at an average price of $220.31, for a total transaction of $17,184,180.00. Following the sale, the director directly owned 1,076,198 shares of the company’s stock, valued at approximately $237,097,181.38. This trade represents a 6.76% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 156,530 shares of company stock valued at $33,914,062. Corporate insiders own 5.05% of the company’s stock.

Natera Stock Performance

Shares of Natera stock opened at $215.31 on Monday. Natera, Inc. has a one year low of $131.81 and a one year high of $256.36. The company has a market cap of $30.83 billion, a PE ratio of -132.09 and a beta of 1.56. The business has a 50-day simple moving average of $204.19 and a 200-day simple moving average of $216.13.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.